DAA TREATMENT IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA: DOES TREATMENT TIMING CHANGE HCC RECURRENCE RISK?

Shalaby Sarah; Zanetto Alberto; Ferrarese Alberto; Becchetti Chiara; Sciarrone Salvatore Stefano; Pellone Monica; DArcangelo Francesca; Gambato Martina; Germani Giacomo; Senzolo Marco; Russo Francesco Paolo; Cillo Umberto; Burra Patrizia

首页> 外文期刊>Transplant international : >DAA TREATMENT IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA: DOES TREATMENT TIMING CHANGE HCC RECURRENCE RISK?

【24h】

DAA TREATMENT IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA: DOES TREATMENT TIMING CHANGE HCC RECURRENCE RISK?

机译：DAA治疗在接受肝细胞癌的肝移植患者中：治疗时间是否改变HCC复发风险？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Transplant international :》 |2019年第s2期|共1页
作者
Shalaby Sarah; Zanetto Alberto; Ferrarese Alberto; Becchetti Chiara; Sciarrone Salvatore Stefano; Pellone Monica; DArcangelo Francesca; Gambato Martina; Germani Giacomo; Senzolo Marco; Russo Francesco Paolo; Cillo Umberto; Burra Patrizia;
展开▼
作者单位

Padua Univ Hosp Dept Surg Oncol &

Gastroenterol Multivisceral Transplant Unit Padua Italy;

Padua Univ Hosp Dept Surg Oncol &

Gastroenterol Multivisceral Transplant Unit Padua Italy;

Padua Univ Hosp Dept Surg Oncol &

Gastroenterol Multivisceral Transplant Unit Padua Italy;

Padua Univ Hosp Dept Surg Oncol &

Gastroenterol Multivisceral Transplant Unit Padua Italy;

Padua Univ Hosp Dept Surg Oncol &

Gastroenterol Multivisceral Transplant Unit Padua Italy;

Padua Univ Hosp Dept Surg Oncol &

Gastroenterol Multivisceral Transplant Unit Padua Italy;

Padua Univ Hosp Dept Surg Oncol &

Gastroenterol Multivisceral Transplant Unit Padua Italy;

Padua Univ Hosp Dept Surg Oncol &

Gastroenterol Multivisceral Transplant Unit Padua Italy;

Padua Univ Hosp Dept Surg Oncol &

Gastroenterol Multivisceral Transplant Unit Padua Italy;

Padua Univ Hosp Dept Surg Oncol &

Gastroenterol Multivisceral Transplant Unit Padua Italy;

Padua Univ Hosp Dept Surg Oncol &

Gastroenterol Multivisceral Transplant Unit Padua Italy;

Padua Univ Hosp Dept Surg Oncol &

Gastroenterol Hepatobiliary Surg &

Liver Transplant Unit Padua;

Padua Univ Hosp Dept Surg Oncol &

Gastroenterol Multivisceral Transplant Unit Padua Italy;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类器官移植术;
关键词

相似文献

外文文献
中文文献
专利

1. DAA TREATMENT IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA: DOES TREATMENT TIMING CHANGE HCC RECURRENCE RISK? [J] . Shalaby Sarah, Zanetto Alberto, Ferrarese Alberto, Transplant international : . 2019,第S2期

机译：DAA治疗在接受肝细胞癌的肝移植患者中：治疗时间是否改变HCC复发风险？
2. TREATMENT WITH DIRECT-ACTING ANTIVIRALS (DAAS) NEITHER INCREASES THE RISK OF HEPATOCELLULAR CARCINOMA PROGRESSION DURING WAITING LIST NOR RECURRENCE AFTER LIVER TRANSPLANTATION [J] . Pinero Federico, Boin Ilka, Rubinstein Fernando, Transplant international : . 2019,第S2期

机译：用直效抗病毒治疗（DAAs）既不会增加肝移植后等待清单中肝细胞癌进展的风险，也不会复发
3. Treatment of HCV with DAAs in cirrhosis: Risk of early de novo hepatocellular carcinoma (HCC) and impact of HCC on SVR. [J] . Sterling Richard K., Patel Vaishali, Kumral Dennis, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017,第Suppla1期

机译：治疗肝硬化中DAAs的HCV：早期Novo肝细胞癌（HCC）的风险及HCC对SVR的影响。
4. Surgical treatment for hepatocellular carcinoma: the role of living donor liver transplantation [C] . C. VALENTIN GAMAZ, C. E. BROELSCH, M. MALAGO Falk Workshop . 2003

机译：肝细胞癌的外科治疗：生活供体肝移植的作用
5. Sesquiterpene drugs as potential treatment for hepatocellular carcinoma (HCC): Preclinical evaluation of parthenolide administered via transarterial chemoembolization in a rat HCC tumor model. [D] . Chen, Zheng. 2016

机译：倍半萜类药物可作为肝细胞癌（HCC）的潜在治疗方法：在大鼠HCC肿瘤模型中，通过经动脉化学栓塞术施用的小白菊内酯的临床前评估。
6. The Impact of Hepatitis C Virus (HCV) Treatment with Direct-Acting (DAA) on the Incidence of Hepatocellular Carcinoma (HCC) in Patients with Advanced Liver Disease [O] . Charles De Comarmond, Hendren Bajillan, Bailey Guest 2017

机译：直接作用（DAA）治疗丙型肝炎病毒（HCV）对晚期肝病患者肝细胞癌（HCC）发病率的影响
7. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: Issue of the interval between HCC treatment and antiviral therapy [O] . Pei-Chien Tsai, Chung-Feng Huang, Ming-Lung Yu 2017

机译：丙型肝炎病毒相关肝细胞癌患者发生意外的早期肿瘤复发：在无干扰素治疗中：HCC治疗与抗病毒治疗之间的间隔问题

DAA TREATMENT IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA: DOES TREATMENT TIMING CHANGE HCC RECURRENCE RISK?

著录项

相似文献

相关主题

期刊订阅